Company profile for Triplet Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are developing a fundamentally different treatment for repeat expansion disorders — including Huntington’s disease, myotonic dystrophy and spinocerebellar ataxias — by addressing the underlying cause of the genetic dysfunction that drives disease onset and progression. To accomplish this goal, we’ve assembled a team with decades of expertise across drug discovery, genetics, clinical research and operations. We’r...
We are developing a fundamentally different treatment for repeat expansion disorders — including Huntington’s disease, myotonic dystrophy and spinocerebellar ataxias — by addressing the underlying cause of the genetic dysfunction that drives disease onset and progression. To accomplish this goal, we’ve assembled a team with decades of expertise across drug discovery, genetics, clinical research and operations. We’re supported by a top-tier syndicate of investors who share our commitment to transforming the lives of patients and families affected by repeat expansion disorders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
One Kendall Square 1400W, Suite 14201 Cambridge, MA 02139
Telephone
Telephone
781.299.7830
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

IPhEB Russia

Not Confirmed

envelop Contact Supplier

IPhEB Russia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://endpts.com/atlas-backed-biotech-focused-on-huntingtons-disease-shuts-down-less-than-three-years-after-launch/

Max Gelman ENDPTS
12 Oct 2022

https://www.businesswire.com/news/home/20210427006117/en/Triplet-Therapeutics-Presents-Preclinical-Data-for-TTX-3360-Announces-Equity-Pledge-at-the-CHDI-Foundation%E2%80%99s-16th-Annual-HD-Therapeutics-Conference

BUSINESSWIRE
28 Apr 2021

https://www.businesswire.com/news/home/20210427006117/en

BUSINESSWIRE
27 Apr 2021

https://www.statnews.com/2021/01/05/something-ventured-q4-2019/

Kate Sheridan STATNEWS
05 Jan 2021

https://www.businesswire.com/news/home/20200818005129/en

BUSINESSWIRE
17 Aug 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty